CryoCell International (CCEL)
(Delayed Data from AMEX)
$6.20 USD
-0.29 (-4.47%)
Updated Aug 30, 2024 11:35 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for CryoCell International Inc falls in the month of November .
All items in Millions except EPS data.
11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 | |
---|---|---|---|---|---|
Sales | 31 | 30 | 29 | 31 | 32 |
Cost Of Goods | 8 | 9 | 9 | 10 | 10 |
Gross Profit | 23 | 22 | 20 | 21 | 22 |
Selling & Adminstrative & Depr. & Amort Expenses | 35 | 18 | 16 | 14 | 17 |
Income After Depreciation & Amortization | -12 | 4 | 4 | 8 | 5 |
Non-Operating Income | 0 | 1 | 0 | -1 | 0 |
Interest Expense | 1 | 2 | 1 | 2 | 2 |
Pretax Income | -13 | 3 | 3 | 5 | 3 |
Income Taxes | -4 | 1 | 1 | 1 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | 3 | 2 | 4 | 2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | 3 | 2 | 4 | 2 |
Depreciation Footnote | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | 6 | 5 | 8 | 6 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -12 | 4 | 4 | 8 | 5 |
Earnings Per Share Data | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Average Shares | 8.34 | 8.48 | 8.36 | 8.00 | 7.93 |
Diluted EPS Before Non-Recurring Items | 0.46 | 0.33 | 0.25 | 0.44 | 0.29 |
Diluted Net EPS (GAAP) | -1.14 | 0.33 | 0.25 | 0.45 | 0.27 |
Fiscal Year end for CryoCell International Inc falls in the month of November .
All items in Millions except EPS data.
5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | |
---|---|---|---|---|---|
Sales | 8.04 | 7.85 | 7.88 | 7.87 | 7.77 |
Cost Of Goods | 2.02 | 2.16 | 2.08 | 2.16 | 2.14 |
Gross Profit | 6.02 | 5.69 | 5.80 | 5.71 | 5.63 |
SG&A, R&D, and Dept/Amort Expenses | 4.63 | 4.86 | 21.97 | 4.55 | 4.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1.39 | 0.83 | -16.17 | 1.16 | 1.03 |
Non-Operating Income | 0.41 | 0.23 | 0.01 | 0.38 | -0.21 |
Interest Expense | 0.33 | 0.26 | -0.17 | 0.47 | 0.47 |
Pretax Income | 1.47 | 0.79 | -15.99 | 1.07 | 0.35 |
Income Taxes | 0.82 | 0.24 | -4.80 | 0.39 | 0.13 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.66 | 0.56 | -11.19 | 0.68 | 0.22 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.66 | 0.56 | -11.19 | 0.68 | 0.22 |
Earnings Per Share Data | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 |
---|---|---|---|---|---|
Average Shares | 8.23 | 8.33 | 8.34 | 8.34 | 8.33 |
Diluted EPS Before Non-Recurring Items | 0.08 | 0.07 | 0.26 | 0.08 | 0.03 |
Diluted Net EPS (GAAP) | 0.08 | 0.07 | -1.34 | 0.08 | 0.03 |